Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market SetbacksBenzinga • 11/08/24
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.The Motley Fool • 11/08/24
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual MeetingPRNewsWire • 11/05/24
Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded marketFast Company • 11/05/24
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.Barrons • 11/04/24
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer SymposiumPRNewsWire • 11/01/24
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointment - BoAProactive Investors • 10/31/24